and investigate the relationship between high-risk plaque features and ischemia. Carol Holt, Elucid’s vice president of Clinical Development, is an accomplished and multifaceted life sciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback